General Information of Drug (ID: DMTPQ84)

Drug Name
(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE Drug Info
Synonyms
Corticosterone; CORTICOSTERONE; 50-22-6; 17-Deoxycortisol; Reichstein's substance H; Kendall's compound B; Corticosteron; 11beta,21-Dihydroxyprogesterone; Compound B; Reichstein's B; 11-Hydroxycorticoaldosterone; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 4-Pregnene-11beta,21-diol-3,20-dione; 11,21-Dihydroxyprogesterone; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; UNII-W980KJ009P; CCRIS 6753; 11-beta,21-Dihydroxypregn-3,20-dione; CHEBI:16827; NSC9705; corticosterone
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5753
ChEBI ID
CHEBI:16827
CAS Number
CAS 50-22-6
TTD Drug ID
DMTPQ84
VARIDT Drug ID
DR00499
INTEDE Drug ID
DR0382

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vamorolone DM047HI Duchenne muscular dystrophy 8C70.1 Approved [12]
CORT125281 DMHBOUX Prostate cancer 2C82.0 Phase 2 [13]
ISIS-GCCR DMICMNU Diabetic complication 5A2Y Phase 2 [14]
ORIC-101 DMR12S0 Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
AZD9567 DMAXHC0 Rheumatoid arthritis FA20 Phase 1 [12]
A-348441 DM25CBW Type-2 diabetes 5A11 Phase 1 [15]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [16]
deoxycorticosterone DMW6YLS Discovery agent N.A. Investigative [3]
LGD-5552 DM67KWM Discovery agent N.A. Investigative [17]
AL-43 DMLEDHR Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GLYCYRRHIZIN DM8M2N3 Influenza virus infection 1E30-1E32 Phase 3 [19]
BVT.2733 DM6RUKX Lupus 4A40 Phase 3 [20]
INCB13739 DMLQ3PO Type-2 diabetes 5A11 Phase 2a [21]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [22]
JTT-654 DM50M2R Type-2 diabetes 5A11 Phase 2 [23]
RG-4929 DMT4QRD Metabolic disorder 5C50-5D2Z Phase 2 [23]
BMS-770767 DMTVGY7 Hypercholesterolaemia 5C80.0 Phase 2 [23]
UE-2343 DMIERPK Alzheimer disease 8A20 Phase 2 [24]
AZD-4017 DML9M5S Ocular hypertension 9C61.01 Phase 2 [23]
Xanamem DM580GT Alzheimer disease 8A20 Phase 1/2 [25]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aldosterone DM9S2JW Hypertension BA00-BA04 Approved [26]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [27]
Fludrocortisone DMUDIR8 Addison disease 5A74.0 Approved [28]
Desoxycorticosterone Acetate DMS0AFE Discovery agent N.A. Approved [27]
Desoxycorticosterone Pivalate DMSA4B3 Addison disease 5A74.0 Approved [29]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [30]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [27]
Finerenone DMM4FJ3 Chronic kidney disease GB61 Approved [31]
ZK-91587 DMJ94L0 Cardiovascular disease BA00-BE2Z Phase 2 [32]
Nerenone DMBJ3GL Diabetic nephropathy GB61.Z Phase 2 [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [34]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [35]
Methotrexate DM2TEOL Anterior urethra cancer Approved [36]
Folic Acid DMEMBJC Colorectal carcinoma Approved [37]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [36]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [36]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [38]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [36]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [4]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [40]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [41]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [42]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [43]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [44]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [45]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [46]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [47]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [41]
Verapamil DMA7PEW Angina pectoris BA40 Approved [48]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [49]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [51]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [52]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [53]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [53]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [54]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [55]
Capsaicin DMGMF6V Back pain ME84.Z Approved [56]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [57]
⏷ Show the Full List of 20 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epinephrine DM3KJBC Acute asthma CA23 Approved [58]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [58]
Norepinephrine DMOUC09 Alopecia ED70 Approved [58]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [59]
Quercetin DM3NC4M Obesity 5B81 Approved [60]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [61]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [62]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [63]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [64]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [66]
Quercetin DM3NC4M Obesity 5B81 Approved [60]
Fructose DM43AN2 Vomiting MD90 Approved [67]
Oxcarbazepine DM5PU6O Epilepsy 8A60-8A68 Approved [68]
Estrone DM5T6US Acne vulgaris ED80 Approved [69]
Testosterone DM7HUNW Hot flushes GA30 Approved [70]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [71]
Dienestrol DMBSXI0 Atrophic vaginitis GA30.2 Approved [69]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [69]
Masoprocol DMMVNZ0 Prostate cancer 2C82.0 Approved [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [72]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [72]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [72]
Capsaicin DMGMF6V Back pain ME84.Z Approved [73]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [74]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [75]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [76]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [77]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [78]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [79]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fomepizole DM6VOWQ Athylene glycol or methanol poisoning NE61 Approved [80]
Ademetionine DMYQDBO Hepatic fibrosis DB93.0 Approved [81]
Theophylline DMRJFN9 Bronchitis CA20 Approved [79]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [82]
Ethanol DMDRQZU Chronic pain MG30 Approved [83]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [84]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [85]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [86]
Didanosine DMI2QPE Human immunodeficiency virus infection 1C62 Approved [79]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [87]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [88]
Testosterone DM7HUNW Hot flushes GA30 Approved [89]
Triamcinolone DM98IXF Acute adrenal insufficiency Approved [90]
Aldosterone DM9S2JW Hypertension BA00-BA04 Approved [91]
Betamethasone DMAHJEF Acute adrenal insufficiency Approved [90]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [62]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [86]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [90]
Budesonide DMJIBAW Allergic rhinitis CA08.0 Approved [90]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [92]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [93]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [93]
Hydroxyflutamide DMGIZF5 Prostate cancer 2C82.0 Approved [93]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [94]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [95]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [96]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [97]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [98]
Selenium DM25CGV N. A. N. A. Approved [99]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [100]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [101]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [102]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [103]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [104]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [105]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [106]
Capsaicin DMGMF6V Back pain ME84.Z Approved [73]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [53]
Quinidine DMLPICK N. A. N. A. Approved [107]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [108]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2A6 (CYP2A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tegafur DM31ZQM Solid tumour/cancer 2A00-2F9Z Approved [109]
Methoxsalen DME8FZ9 Cutaneous T-cell lymphoma 2B01 Approved [110]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [111]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [112]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [84]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [43]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [113]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [115]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [116]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [117]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [53]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [52]
Capsaicin DMGMF6V Back pain ME84.Z Approved [73]
Zafirlukast DMHNQOG Asthma CA23 Approved [118]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [53]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [119]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [52]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [120]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [121]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [122]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [123]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [124]
Clopidogrel DMOL54H Acute coronary syndrome BA41 Approved [125]
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [126]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [127]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [128]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [129]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [130]
Quercetin DM3NC4M Obesity 5B81 Approved [60]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [131]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [132]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [133]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [71]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [86]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [134]
Thiamphenicol DMDRKH2 Bacterial infection 1A00-1C4Z Approved [135]
Ampicillin DMHWE7P Acute epiglottitis Approved [130]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein GREB1 (GREB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [136]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [137]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [138]
Testosterone DM7HUNW Hot flushes GA30 Approved [139]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [140]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [71]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [141]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [137]
Nandrolone DMFWKG1 Osteoporosis FB83.0 Approved [142]
Mestranol DMG3F94 Contraception QA21 Approved [137]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [143]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [144]
D-glucose 6-phosphate DMNRW57 N. A. N. A. Investigative [145]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [146]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [146]
Gefitinib DM15F0X Colon adenocarcinoma Approved [147]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [79]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [148]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [149]
Methotrexate DM2TEOL Anterior urethra cancer Approved [150]
Quercetin DM3NC4M Obesity 5B81 Approved [151]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [152]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [153]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Angiotensinogen (AGT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [154]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [7]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [155]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [156]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [157]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [158]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [159]
Quercetin DM3NC4M Obesity 5B81 Approved [60]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [160]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [161]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aldosterone DM9S2JW Hypertension BA00-BA04 Approved [162]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [163]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [164]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [86]
Potassium Chloride DMMTAJC Hypokalemia 5C77 Approved [165]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [166]
Mitotane DMU1GX0 Adrenocortical carcinoma 2D11.Z Approved [167]
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [164]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [168]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [169]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [9]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [163]
Quercetin DM3NC4M Obesity 5B81 Approved [170]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [86]
Ethanol DMDRQZU Chronic pain MG30 Approved [171]
Potassium Chloride DMMTAJC Hypokalemia 5C77 Approved [165]
Mitotane DMU1GX0 Adrenocortical carcinoma 2D11.Z Approved [172]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [79]
Dalcetrapib DMKNCVM Acute coronary syndrome BA41 Phase 3 [173]
Anacetrapib DMP2BFG Arteriosclerosis BD40 Phase 3 [173]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) TTN7BL9 DHI1_HUMAN Inhibitor [2]
Glucocorticoid receptor messenger RNA (GCR mRNA) TTOZRK6 GCR_HUMAN Agonist [3]
Mineralocorticoid receptor (MR) TT26PHO MCR_HUMAN Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [6]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Regulation of Drug Effects [7]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [8]
Cytochrome P450 11B1, mitochondrial (CYP11B1) OTKKL894 C11B1_HUMAN Biotransformations [9]
Cytochrome P450 11B2, mitochondrial (CYP11B2) OTIOLWYN C11B2_HUMAN Biotransformations [10]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [11]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Gene/Protein Processing [11]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Gene/Protein Processing [11]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [11]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [11]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2869).
2 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
3 Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9.
4 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
5 Studies on pharmacokinetic drug interaction potential of vinpocetine. Medicines (Basel). 2015 Jun 5;2(2):93-105.
6 Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4.
7 Steroid profiling in H295R cells to identify chemicals potentially disrupting the production of adrenal steroids. Toxicology. 2017 Apr 15;381:51-63.
8 Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 2005 Jan;312(1):144-52. doi: 10.1124/jpet.104.073916. Epub 2004 Sep 13.
9 Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
10 Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives. J Med Chem. 2011 Apr 14;54(7):2307-19.
11 Prenatal ethanol exposure induces dynamic changes of expression and activity of hepatic cytochrome P450 isoforms in male rat offspring. Reprod Toxicol. 2022 Apr;109:101-108. doi: 10.1016/j.reprotox.2022.03.002. Epub 2022 Mar 14.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
15 Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90.
16 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
17 Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
18 Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1721-7.
19 Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
20 Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
21 Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
22 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
23 New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.
26 Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
27 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
28 Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
29 Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
30 Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
31 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
32 ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
34 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
35 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
36 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
37 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
38 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
39 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
40 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
41 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
42 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
43 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
44 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
45 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
46 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
47 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
48 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
49 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
50 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
51 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
52 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
53 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
54 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
55 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
56 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
57 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
58 Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
59 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
60 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
61 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
62 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
63 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
64 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
65 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
66 Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003 Feb;67(2):93-9. doi: 10.1016/s0010-7824(02)00473-0.
67 Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest. 2007 Dec;117(12):3979-87. doi: 10.1172/JCI32249.
68 Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology. 2001 Jan 9;56(1):31-6. doi: 10.1212/wnl.56.1.31.
69 Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and -fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27.
70 Testosterone or 17{beta}-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. J Endocrinol. 2011 Aug;210(2):219-29. doi: 10.1530/JOE-10-0497. Epub 2011 Jun 1.
71 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
72 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
73 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
74 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
75 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
76 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
77 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
78 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
79 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
80 Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
81 Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
82 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
83 An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
84 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
85 Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
86 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
87 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
88 The human mineralocorticoid receptor only partially differentiates between different ligands after expression in fission yeast. FEMS Yeast Res. 2005 Apr;5(6-7):627-33. doi: 10.1016/j.femsyr.2004.12.007.
89 The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor. Mol Pharmacol. 2007 Feb;71(2):473-82. doi: 10.1124/mol.106.031112. Epub 2006 Nov 14.
90 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
91 Regulation of mineralocorticoid receptor expression during neuronal differentiation of murine embryonic stem cells. Endocrinology. 2010 May;151(5):2244-54. doi: 10.1210/en.2009-0753. Epub 2010 Mar 5.
92 Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact. 2009 May 15;179(2-3):288-96.
93 TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
94 Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
95 Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
96 Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
97 Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
98 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
99 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
100 Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
101 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
102 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
103 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
104 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
105 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
106 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
107 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
108 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
109 Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
110 Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x.
111 Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res. 2001 May;92(5):524-8. doi: 10.1111/j.1349-7006.2001.tb01125.x.
112 CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
113 Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
114 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
115 Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
116 A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4. doi: 10.1006/bbrc.2001.4422.
117 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
118 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
119 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
120 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
121 Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
122 Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
123 Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
124 Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
125 Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
126 Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
127 Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
128 Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
129 Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
130 Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem. 2007 Jan 19;282(3):1727-37. doi: 10.1074/jbc.M609822200. Epub 2006 Nov 30.
131 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
132 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
133 Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
134 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
135 Human nasal olfactory epithelium as a dynamic marker for CNS therapy development. Exp Neurol. 2011 Dec;232(2):203-11. doi: 10.1016/j.expneurol.2011.09.002. Epub 2011 Sep 16.
136 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
137 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
138 Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
139 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
140 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
141 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
142 Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18.
143 G6PC2 Modulates Fasting Blood Glucose In Male Mice in Response to Stress. Endocrinology. 2016 Aug;157(8):3002-8. doi: 10.1210/en.2016-1245. Epub 2016 Jun 14.
144 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
145 Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP). J Biol Chem. 2004 Apr 2;279(14):13976-83. doi: 10.1074/jbc.M307756200. Epub 2004 Jan 13.
146 Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
147 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
148 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
149 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
150 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
151 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
152 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
153 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
154 Genistein disrupts glucocorticoid receptor signaling in human uterine endometrial Ishikawa cells. Environ Health Perspect. 2015 Jan;123(1):80-7. doi: 10.1289/ehp.1408437. Epub 2014 Aug 19.
155 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
156 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
157 Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther. 1980 Apr;27(4):533-43. doi: 10.1038/clpt.1980.75.
158 Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008 Jun;26(6):1147-55. doi: 10.1097/HJH.0b013e3282f97dde.
159 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
160 Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J. 1993 Jun;69(6):512-5. doi: 10.1136/hrt.69.6.512.
161 Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999 Mar;33(3):850-5. doi: 10.1161/01.hyp.33.3.850.
162 [Association study between a polymorphism of aldosterone synthetase gene and the pathogenesis of polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi. 2003 Feb;38(2):94-7.
163 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
164 Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):142-53.
165 Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008 Apr 28;584(2-3):424-34. doi: 10.1016/j.ejphar.2008.02.001. Epub 2008 Feb 12.
166 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
167 Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013 May 21;20(3):371-81.
168 Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol Scand Suppl. 2009;(189):14-21.
169 Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens. 2002 May;15(5):389-93. doi: 10.1016/s0895-7061(02)02256-2.
170 Flavonoids exhibit diverse effects on CYP11B1 expression and cortisol synthesis. Toxicol Appl Pharmacol. 2012 Feb 1;258(3):343-50.
171 Autophagy as a compensation mechanism participates in ethanol-induced fetal adrenal dysfunction in female rats. Toxicol Appl Pharmacol. 2018 Apr 15;345:36-47.
172 Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):281-9.
173 Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. J Pharmacol Exp Ther. 2015 Apr;353(1):27-34.